Insider Buying: INmune Bio, Inc. (NASDAQ:INMB) CFO Buys 10,000 Shares of Stock

INmune Bio, Inc. (NASDAQ:INMB) CFO David J. Moss acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The shares were purchased at an average cost of $5.29 per share, for a total transaction of $52,900.00. Following the acquisition, the chief financial officer now owns 1,285,869 shares in the company, valued at $6,802,247.01. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

INmune Bio Trading Down 3.6 %

Shares of INMB opened at $5.31 on Thursday. The stock’s 50-day moving average price is $6.61 and its two-hundred day moving average price is $8.66. INmune Bio, Inc. has a 12 month low of $4.81 and a 12 month high of $14.74. The company has a market capitalization of $105.04 million, a PE ratio of -2.71 and a beta of 1.85.

INmune Bio (NASDAQ:INMB) last announced its earnings results on Thursday, August 1st. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Scotiabank started coverage on INmune Bio in a report on Thursday, August 22nd. They set a “sector outperform” rating and a $22.00 price target on the stock. Raymond James assumed coverage on shares of INmune Bio in a report on Friday, September 27th. They set an “outperform” rating and a $18.00 target price on the stock.

Institutional Investors Weigh In On INmune Bio

Institutional investors have recently modified their holdings of the company. Fermata Advisors LLC lifted its holdings in INmune Bio by 6.9% in the first quarter. Fermata Advisors LLC now owns 31,451 shares of the company’s stock valued at $370,000 after buying an additional 2,025 shares during the period. Westside Investment Management Inc. lifted its stake in shares of INmune Bio by 31.8% in the 2nd quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock valued at $400,000 after purchasing an additional 10,950 shares during the period. Bank of New York Mellon Corp boosted its position in shares of INmune Bio by 124.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after purchasing an additional 32,511 shares in the last quarter. Rhumbline Advisers acquired a new stake in INmune Bio during the second quarter worth approximately $121,000. Finally, Marshall Wace LLP grew its stake in INmune Bio by 332.1% during the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after purchasing an additional 89,091 shares during the period. 12.72% of the stock is owned by institutional investors.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.